Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Combination (Solifenacin + Mirabegron)	727
Overall Study	STARTED	Solifenacin 5 mg	728
Overall Study	STARTED	Solifenacin 10 mg	719
Overall Study	Treated With Double-blind Drug	Combination (Solifenacin + Mirabegron)	725
Overall Study	Treated With Double-blind Drug	Solifenacin 5 mg	728
Overall Study	Treated With Double-blind Drug	Solifenacin 10 mg	719
Overall Study	COMPLETED	Combination (Solifenacin + Mirabegron)	678
Overall Study	COMPLETED	Solifenacin 5 mg	679
Overall Study	COMPLETED	Solifenacin 10 mg	680
Overall Study	NOT COMPLETED	Combination (Solifenacin + Mirabegron)	49
Overall Study	NOT COMPLETED	Solifenacin 5 mg	49
Overall Study	NOT COMPLETED	Solifenacin 10 mg	39

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01908829/flow